德诺苏马布
医学
兰克尔
多发性骨髓瘤
骨吸收
骨密度保护剂
单克隆
骨肉瘤
初生骨
肿瘤科
单克隆抗体
癌症研究
病理
激活剂(遗传学)
内科学
受体
抗体
骨质疏松症
免疫学
骨密度
作者
Olga D. Savvidou,Ioanna K Bolia,George D. Chloros,John Papanastasiou,Panagiotis Koutsouradis,Panayiotis J. Papagelopoulos
出处
期刊:Orthopedics
[SLACK, Inc.]
日期:2017-07-01
卷期号:40 (4): 204-210
被引量:25
标识
DOI:10.3928/01477447-20170627-04
摘要
Denosumab, a human monoclonal antibody that inhibits bone resorption by binding on the receptor activator of the nuclear factor kappa-β ligand, has recently emerged as an additional option in the treatment of musculoskeletal osteolytic tumors. This article focuses on the recent literature regarding the effectiveness of denosumab in the management of giant cell tumor, multiple myeloma, aneurysmal bone cyst, and osteosarcoma. The mechanism of action of denosumab in the management of these tumors and the associated side effects are discussed in detail. [ Orthopedics. 2017; 40(4):204-210.].
科研通智能强力驱动
Strongly Powered by AbleSci AI